Greg Moeck Selected Research

oritavancin

6/2018	A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.
1/2018	Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
1/2018	Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
10/2017	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
2/2017	Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
1/2017	Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
11/2016	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
1/2016	Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
1/2015	Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
6/2014	Single-dose oritavancin in the treatment of acute bacterial skin infections.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Greg Moeck Research Topics

Disease

13	Infections 01/2021 - 01/2013
2	Fever (Fevers) 01/2015 - 06/2014
1	Abscess 01/2018
1	Cellulitis 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Activated Protein C Resistance (APC Resistance) 01/2017
1	Persistent Infection 01/2016
1	Nausea 06/2014
1	Body Weight (Weight, Body) 01/2013
1	Communicable Diseases (Infectious Diseases) 02/2004

Drug/Important Bio-Agent (IBA)

12	oritavancinIBA 06/2018 - 01/2013
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 02/2004
6	LipoglycopeptidesIBA 06/2018 - 01/2013
6	Vancomycin FDA LinkGeneric 01/2018 - 01/2013
3	Daptomycin FDA Link 01/2018 - 01/2013
3	dalbavancinIBA 02/2017 - 01/2014
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2013
1	Cefepime (Maxipime)FDA LinkGeneric 01/2020
1	taniborbactamIBA 01/2020
1	Anti-Infective Agents (Microbicides)IBA 06/2018
1	LipopeptidesIBA 01/2018
1	tedizolidIBA 02/2017
1	Ceftaroline FDA Link 02/2017
1	telavancin FDA Link 02/2017
1	Heparin (Liquaemin)FDA LinkGeneric 01/2017
1	Factor Xa (Coagulation Factor Xa)IBA 01/2017
1	Peptides (Polypeptides)IBA 02/2004

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2018